Open an Account
search icon
3
NOTIFICATIONS
Best Algo trading app in India
Bigul

BLISS GVS PHARMA LTD. - 506197 - Details Of Key Managerial Personnel To Determine Materiality Of Event Or Information And Its Disclosure

 Pursuant to Regulation 30(5) of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, please note that Mr. Gagan Sharma, Managing Director and Mr. Deepak Sawant, Chief Financial Officer of the Company is authorised for the purpose of determining the materiality of an event or information as well as intimating information to Stock Exchange(s) and Ms. Aditi Bhatt Company Secretary of the Company is authorized to make disclosure of information to the Stock Exchange(s).
30-12-2022
Bigul

BLISS GVS PHARMA LTD. - 506197 - Board Meeting Outcome for Outcome Of Board Meeting Held Today I.E. Friday, December 30, 2022 Regarding Appointment Of Chief Financial Officer Of The Company

 Pursuant to Regulation 30 read with Schedule III of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 and SEBI Circular CIR/CFD/CMD/4/2015 dated September 9, 2015, we wish to inform you that the Board of Directors of the Company at their meeting held today i.e. Friday, December 30, 2022 had considered and approved the Appointment of Mr. Deepak Sawant as Chief Financial Officer of the Company w.e.f. today i.e. December 30, 2022. (Disclosure pursuant to SEBI Circular No. CIR/CFD/CMD/4/2015 dated September 09, 2015 is enclosed herewith as 'Annexure-I'). Request you to kindly take the above on record and acknowledge.
30-12-2022
Bigul

BLISS GVS PHARMA LTD. - 506197 - Closure of Trading Window

 This is to inform you that pursuant to Securities Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015 (including any statutory modification(s) or re-enactment(s) thereof, for the time being in force) and in accordance with the Code of Internal Procedures and Conduct for Regulating, Monitoring and Reporting of Trading by Designated Persons, the Trading window for dealing in securities/shares of Bliss GVS Pharma Limited ('the Company') will remain closed for Insiders, Designated Persons and their immediate relatives of the Company with effect from Saturday, October 01, 2022 until 48 hours after the announcement of the Unaudited Financial Results of the Company for the quarter and half year ended September 30, 2022.
30-12-2022
Bigul

BLISS GVS PHARMA LTD. - 506197 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate

 Pursuant to Regulation 39(3) of Securities Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform you that Registrar and Share Transfer Agent of Company M/s. Universal Capital Securities Private Limited has received request for issue of duplicate share certificate consequent to loss of share certificate from the shareholder.
17-12-2022
Bigul

BLISS GVS PHARMA LTD. - 506197 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate

 Pursuant to Regulation 39(3) of Securities Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform you that Registrar and Share Transfer Agent of Company M/s. Universal Capital Securities Private Limited has received request for issue of duplicate share certificate consequent to loss of share certificate from the shareholder.
09-12-2022
Bigul

BLISS GVS PHARMA LTD. - 506197 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate

 Pursuant to Regulation 39(3) of Securities Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform you that Registrar and Share Transfer Agent of Company M/s. Universal Capital Securities Private Limited has intimated regarding issuance of duplicate share certificates cum transmission to legal heir of the deceased shareholder.
28-11-2022
Bigul

BLISS GVS PHARMA LTD. - 506197 - Clarification W.R.T Submission Of Outcome Of The Board Meeting Held On Monday, November 07, 2022

 Please find the attachment.
23-11-2022
Bigul

BLISS GVS PHARMA LTD. - 506197 - Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS

 We would like to inform you that, the ESOP Allotment Committee of the Company at its meeting held on November 23, 2022 has approved the allotment of 2,67,750 equity shares of face value of Re. 1/- each to the eligible employees who have exercised their stock options under Bliss GVS Pharma Limited-Employee Stock Option Plan 2019 ('Bliss GVS ESOP-2019').
23-11-2022
Bigul

BLISS GVS PHARMA LTD. - 506197 - Disclosure Of Related Party Transactions Under Regulation 23(9) Of SEBI (LODR) Regulations, 2015

 Pursuant to Regulation 23(9) of the Securities and Exchange Board of India (Listing Obligations and Disclosures Requirements) Regulations, 2015, please find enclosed herewith a disclosure of Related Party Transactions in the specified format for the half year ended September 30, 2022. Kindly take the same on your record.
21-11-2022
Bigul

BLISS GVS PHARMA LTD. - 506197 - Announcement under Regulation 30 (LODR)-Newspaper Publication

 Pursuant to the provision of Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith the extract copies of newspaper advertisement of Unaudited Financial Results of the Company for the quarter and half year ended September 30, 2022 published in 'The Economic Times & The Free Press Journal' an English Daily and 'Maharashtra Times & Navshakti' a Regional Daily, on November 09, 2022
09-11-2022
Next Page
Close

Let's Open Free Demat Account